Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT04458831 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04458831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Sanofi
Phase
Observational
Overall status
Completed
Start date
August 13, 2020
Completion date
February 23, 2026
Enrollment
583 (actual)
Sites
129

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma